Vimarsana
Biggest News Aggregation in the World

Page 3 - Specific Antigen News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Specific Antigen. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Specific Antigen Today - Breaking & Trending Today

Proteomedix Agrees to Issue Labcorp Exclusive License for Proclarix Blood Test to Detect Prostate Cancer - Vimarsana News

Proteomedix Agrees to Issue Labcorp Exclusive License for Proclarix Blood Test to Detect Prostate Cancer

Labcorp Plans to Develop and Commercialize the Innovative Prostate Cancer Liquid Biopsy Test in the U.S. Proteomedix, a Swiss diagnostics company committed to advancing prostate cancer care, announced

Choose Health Makes More At-Home Blood Tests Available for Private Label Use - Vimarsana News

Choose Health Makes More At-Home Blood Tests Available for Private Label Use

/PRNewswire/ -- Choose Health is excited to expand its popular private label product line to include additional at-home blood tests. A wide variety of...

Essential medical tests you should do - Vimarsana News

Essential medical tests you should do

Routine check-ups help us detect a disease in its early stages which is important in the overall management and treatment outcomes.

Northern Nevada Sierra Medical Center Hosts Inaugural Low-Cost Community Health Fair - Vimarsana News

Northern Nevada Sierra Medical Center Hosts Inaugural Low-Cost Community Health Fair

Northern Nevada Sierra Medical Center (SMC), will host its first community health fair on Wednesday, July 13 from 7 a.m. to 10 a.m. at 625 Innovation Drive near the intersection

Source: 2news.com
Modra Pharmaceuticals Presents In-Depth Data Analysis from Lower Dose Cohort in Phase 2b Study of Oral Taxane ModraDoc006/r in mCRPC Patients at 2022 ASCO Annual Meeting - Vimarsana News

Modra Pharmaceuticals Presents In-Depth Data Analysis from Lower Dose Cohort in Phase 2b Study of Oral Taxane ModraDoc006/r in mCRPC Patients at 2022 ASCO Annual Meeting

ModraDoc006/r at 20-20/200-100mg dosage eliminated neutropenia and significantly decreased neuropathy while maintaining efficacy levels comparable to intravenous (IV) docetaxel Based on strong